Abstract
To evaluate the clinical usefulness of SY 5555, a new oral penem, in the treatment of bacterial pneumonia, a double-blind comparative study, using cefotiam hexetil (CTM-HE) as the control drug, was conducted in various clinical institutes. The drugs were given at a daily dose of 900 mg of SY 5555 or 600 mg of CTM-HE, divided three times a day, for 14 days. 1. The clinical efficacy rates were 90.2% (83/92) for the SY 5555 group and 85.1% (86/101) for the CTM-HE group. The efficacy rates of the two drugs were not significantly different. 2. Bacteriologically, the eradication rates were 77.4%(24/31) for the SY 5555 group and 89.2% (33/37) for the CTM-HE group, showing no statisticaly significant difference between them. 3. Side effects were observed 8 of 111 patients in the SY 5555 group and 7 of 111 patients in the CTM-HE group. The main side effect was gastrointestinal symptoms in both groups. 4. The incidence of abnormal changes in laboratory findings was 19.6% (21/107) in the SY 5555 group and 16.8% (18/107) in the CTM-HE group. 5. The total usefulness rates were 88.3% (83/94) in the SY 5555 group and 81.4% (83/102) in the CTM-HE group. There was no significant difference between the two groups. The above results showed that in terms of efficacy and safety the SY 5555 group was equal to the CTM-HE group. SY 5555 was concluded to be a useful drug for the treatment of bacterial pneumonia.
Original language | English |
---|---|
Pages (from-to) | 616-638 |
Number of pages | 23 |
Journal | CHEMOTHERAPY |
Volume | 42 |
Issue number | 5 |
DOIs | |
Publication status | Published - 1994 |
Externally published | Yes |
All Science Journal Classification (ASJC) codes
- Pharmacology (medical)
- Infectious Diseases
- Pharmacology
- Drug Discovery
- Oncology